Medicure Inc. (MPH.V)
TSXV · CAD · Healthcare · Drug Manufacturers - Specialty & Generic
CA$4.44 (+0.91%) as of
Key statistics
- Market cap
- 46.34M
- Forward P/E
- -14.32
- EPS (TTM)
- -0.7100
- Dividend yield
- 0.00%
- 52-week range
- 0.8500 – 4.9500
- Beta
- 1.15
- Revenue (TTM)
- 32.08M
- Profit margin
- -23.23%
- Volume
- 5.20k
About Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Winnipeg, MB, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.